02.26.15
Nattopharma ASA along with Hofseth BioCare (HBC), are collaborating to combine MenaQ7 Vitamin K2 as MK-7 and OmeGo EFA from Salmon Oil for a new heart health ingredient. The companies said the blend provides support for improved arterial elasticity while reducing oxLDL GP, a new cardiovascular marker.
NattoPharma's new ingredient, MenaQ7 PURE, is a nature-identical synthetic vitamin K2 as menaquinone-7 (MK-7). Meanwhile, OmeGo is a 100% traceable, sustainably-sourced salmon oil balanced EFA. The companies’ combination, which will be launched first in the U.S., is backed by NattoPharma’s recently issued U.S. Patent for the use of K2 in food products for cardiovascular health (8,354,129 & 8,728,553), and Canadian Patent for the use of vitamin K2 in combination with omega-3 fatty acids for benefits related to bone, cartilage and the cardiovascular system (no. 2,657,748).
“Omega-3 has been established as a cardiovascular health ingredient, as it has earned a qualified Health Claim in the U.S. for the reduction in risk of Coronary Heart Disease. Meanwhile, MenaQ7 Vitamin K2 as MK-7 has been clinically shown to increase arterial flexibility by promoting the most potent inhibitor of arterial calcification: the activatgion of Matrix Gla Protein (MGP),” said Hogne Vik, NattoPharma CEO. “By balancing calcium metabolism, vitamin K2 offers a potential synergistic role with omega-3 that could result in unsurpassed cardiovascular formulas that also deliver bone health benefits.”
“There is emerging substantiated evidence that a new marker, oxLDL Beta 2 Glycoprotein Complex 1 (oxLDL GP), is directly tied to the risk of having a cardiac event, and the scientific community agrees it is a better marker of cardiac event predictability than cholesterol and/or triglycerides,” explained Matt Mixter, managing director – U.S. for HBC. “Our human trials produced evidence substantiating OmeGo’s ability to lower this marker, which is a highly differentiable market position compared to commodity grade oils affecting less relevant markers.”
For more information: www.nattopharma.com; www.hofsethbiocare.no
NattoPharma's new ingredient, MenaQ7 PURE, is a nature-identical synthetic vitamin K2 as menaquinone-7 (MK-7). Meanwhile, OmeGo is a 100% traceable, sustainably-sourced salmon oil balanced EFA. The companies’ combination, which will be launched first in the U.S., is backed by NattoPharma’s recently issued U.S. Patent for the use of K2 in food products for cardiovascular health (8,354,129 & 8,728,553), and Canadian Patent for the use of vitamin K2 in combination with omega-3 fatty acids for benefits related to bone, cartilage and the cardiovascular system (no. 2,657,748).
“Omega-3 has been established as a cardiovascular health ingredient, as it has earned a qualified Health Claim in the U.S. for the reduction in risk of Coronary Heart Disease. Meanwhile, MenaQ7 Vitamin K2 as MK-7 has been clinically shown to increase arterial flexibility by promoting the most potent inhibitor of arterial calcification: the activatgion of Matrix Gla Protein (MGP),” said Hogne Vik, NattoPharma CEO. “By balancing calcium metabolism, vitamin K2 offers a potential synergistic role with omega-3 that could result in unsurpassed cardiovascular formulas that also deliver bone health benefits.”
“There is emerging substantiated evidence that a new marker, oxLDL Beta 2 Glycoprotein Complex 1 (oxLDL GP), is directly tied to the risk of having a cardiac event, and the scientific community agrees it is a better marker of cardiac event predictability than cholesterol and/or triglycerides,” explained Matt Mixter, managing director – U.S. for HBC. “Our human trials produced evidence substantiating OmeGo’s ability to lower this marker, which is a highly differentiable market position compared to commodity grade oils affecting less relevant markers.”
For more information: www.nattopharma.com; www.hofsethbiocare.no
